Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SutroVax has generated preclinical proof of concept versus the standard of care vaccines and intends to advance SVX-XP into the clinic as a future successor to SVX-24.
Lead Product(s): SVX-24
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing March 26, 2020